Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Ingrid Delaet Sells 1,091 Shares of Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Ingrid Delaet sold 1,091 shares of the company’s stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $135.00, for a total value of $147,285.00. Following the completion of the sale, the insider now owns 2,507 shares in the company, valued at $338,445. This trade represents a 30.32 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Neurocrine Biosciences Trading Down 0.4 %

Shares of Neurocrine Biosciences stock opened at $134.96 on Friday. Neurocrine Biosciences, Inc. has a twelve month low of $110.95 and a twelve month high of $157.98. The firm has a market capitalization of $13.66 billion, a PE ratio of 36.18 and a beta of 0.34. The firm’s 50-day moving average price is $123.59 and its 200 day moving average price is $130.64.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on NBIX. Raymond James restated an “outperform” rating and set a $155.00 price objective on shares of Neurocrine Biosciences in a report on Thursday, October 10th. Wedbush reiterated an “outperform” rating and issued a $148.00 target price on shares of Neurocrine Biosciences in a research note on Monday. Piper Sandler upgraded shares of Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $131.00 to $159.00 in a research report on Thursday, August 29th. Royal Bank of Canada reduced their price objective on Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating on the stock in a research report on Friday, October 4th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $155.00 price objective on shares of Neurocrine Biosciences in a research note on Monday, September 16th. Five equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $166.00.

Institutional Investors Weigh In On Neurocrine Biosciences

A number of large investors have recently made changes to their positions in NBIX. Ashton Thomas Private Wealth LLC purchased a new position in shares of Neurocrine Biosciences during the 2nd quarter worth $28,000. Innealta Capital LLC purchased a new position in Neurocrine Biosciences during the second quarter worth about $30,000. EdgeRock Capital LLC acquired a new position in Neurocrine Biosciences in the 2nd quarter valued at about $35,000. Blue Trust Inc. grew its stake in shares of Neurocrine Biosciences by 171.9% in the 3rd quarter. Blue Trust Inc. now owns 348 shares of the company’s stock valued at $40,000 after buying an additional 220 shares during the period. Finally, Plato Investment Management Ltd increased its holdings in shares of Neurocrine Biosciences by 44.1% during the 2nd quarter. Plato Investment Management Ltd now owns 425 shares of the company’s stock worth $59,000 after buying an additional 130 shares during the last quarter. 92.59% of the stock is currently owned by hedge funds and other institutional investors.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.